GoNitro FDA Approval History
GoNitro (nitroglycerin) is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.
GoNitro was approved by the FDA via the 505(b) regulatory pathway using previously reported safety and efficacy data. Clinical data demonstrated that the sublingual absorption of nitroglycerin was higher following the administration of GoNitro compared to Nitrolingual Pumpspray (nitroglycerin lingual spray).
GoNitro is supplied as single dose packets of crystal granules which are placed under the tongue at the onset of an angina attack. The most common side effects include headache, dizzinesss and paresthesia.
Development Timeline for GoNitro
|Jun 14, 2016||Espero Pharmaceuticals Receives FDA Approval for GoNitro (nitroglycerin) Sublingual Powder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.